ACTU
USDActuate Therapeutics Inc. Common stock
Echtzeitkurs
Kursdiagramm
Schlüsselkennzahlen
Marktkennzahlen
Eröffnung
$6.500
Hoch
$6.660
Tief
$6.461
Volumen
0.02M
Unternehmensfundamentaldaten
Marktkapitalisierung
153.2M
Branche
Biotechnologie
Land
United States
Handelsstatistiken
Durchschnittliches Volumen
0.07M
Börse
NGM
Währung
USD
52-Wochen-Spanne
Ähnliche Nachrichten
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $20 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics with a Buy and maintains $20 price target.
Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months
Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of care and novel immunotherapiesRecent financing provides extended runway through
Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option
CHICAGO and FORT WORTH, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for
Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock
CHICAGO and FORT WORTH, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for
Actuate Therapeutics Announces Proposed Public Offering of Common Stock
CHICAGO and FORT WORTH, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for
Ähnliche Aktien
Bleiben Sie auf dem Laufenden
Preisalarme setzen, KI-Analyse-Updates und Echtzeit-Marktnachrichten erhalten.